March 22, 2024
A New York federal judge on Thursday denied class certification in litigation claiming GlaxoSmithKline lied about the "Maximum Strength" label on certain Robitussin cough syrup products, saying although the plaintiffs' lack of receipts does not warrant GSK's bid for summary judgment, it's enough to dismiss the customers' request for certification.
November 16, 2021
Pharmaceutical giant Pfizer won the partial dismissal of a proposed class action in New York federal court Monday accusing it of misleading consumers with its "Maximum Strength" labeling of Robitussin cough syrup, but it failed to get the suit's nationwide class allegations stricken.